Overview

BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Status:
Not yet recruiting
Trial end date:
2027-05-31
Target enrollment:
Participant gender:
Summary
This is a three-stage study, consisting of Phase Ia dose-escalation, Phase Ib dose expansion, and a Phase II component.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Xcovery Holding Company, LLC